INmune Bio's MINDFuL Trial Featured at AD/PD 2026 as Successful Example of Precision Approach to Clinical Trials Targeting Inflammation in Early Alzheimer's Disease.
ByAinvest
Thursday, Mar 19, 2026 8:02 am ET1min read
INMB--
INmune Bio's MINDFuL trial was featured at AD/PD 2026 as a successful example of targeting inflammation in early Alzheimer's disease. The trial's biomarker enrichment strategy aligned with the mechanism of action, identifying patients most likely to respond. Dr. Malú Gámez Tansey, a neurology professor, highlighted the trial as a blueprint for Alzheimer's drug development. INmune Bio is advancing a Phase 2b/3 registrational program for XPro1595 in enriched early Alzheimer's patients.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet